Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.12880 http://scihub22266oqcxt.onion/10.1111/bcp.12880 C4876182!4876182!26757427     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Clin+Pharmacol 2016 ; 81 (6): 1021-9 Nephropedia Template TP {{tp|p=26757427|t=2016. N?acetylcysteine for non?paracetamol drug?induced liver injury: a systematic review |pdf=|usr=}}{{26757427}} gab.com Text N acetylcysteine for non paracetamol drug induced liver injury: a systematic review JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26757427 #FOAvip Aims: N?acetylcysteine (NAC) may be useful in the management of non?paracetamol drug?induced liver injury (DILI). Our objective was to review systematically evidence for the use of NAC as a therapeutic option for non?paracetamol DILI. Methods: We searched for randomized controlled trials (RCTs) and prospective cohort studies. We searched several bibliographic databases, grey literature sources, conference proceedings and ongoing trials. Our pre?specified primary outcomes were all cause and DILI related mortality, time to normalization of liver biochemistry and adverse events. Secondary outcomes were proportion receiving liver transplant, time to transplantation, transplant?free survival and hospitalization duration. Results: We identified one RCT of NAC vs. placebo in patients with non?paracetamol acute liver failure. There was no difference in the primary outcomes of overall survival at 3 weeks between NAC [70%, 95% confidence interval (CI) = 60%, 81%, n = 81] and placebo (66%, 95% CI = 56%, 77%, n = 92). NAC significantly improved the secondary outcomes of transplant?free survival compared with placebo: 40% NAC (95% CI = 28%, 51%) vs. 27% placebo (95% CI = 18%, 37%). A subgroup analysis according to aetiology found improved transplant?free survival in patients with non?paracetamol DILI, NAC (58%, n = 19) vs. placebo (27%, n = 26), odds ratio (OR) 0.27 (95% CI = 0.076, 0.942). Overall survival was similar, NAC (79%) vs. placebo (65%);, OR 0.50 (95% CI = 0.13, 1.98). Conclusion: Current available evidence is limited and does not allow for any firm conclusions to be made regarding the role of NAC in non?paracetamol DILI. We therefore highlight the need for further research in this area. Twit Text FOAVip N acetylcysteine for non paracetamol drug induced liver injury: a systematic review ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26757427 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26757427 #FOAvip English Wikipedia <ref>{{Cite pmid|26757427}}</ref> N?acetylcysteine for non?paracetamol drug?induced liver injury: a systematic review #MMPMID26757427 Chughlay MF; Kramer N; Spearman CW; Werfalli M; Cohen K Br J Clin Pharmacol 2016[Jun]; 81 (6): 1021-9 PMID26757427show ga Aims: N?acetylcysteine (NAC) may be useful in the management of non?paracetamol drug?induced liver injury (DILI). Our objective was to review systematically evidence for the use of NAC as a therapeutic option for non?paracetamol DILI. Methods: We searched for randomized controlled trials (RCTs) and prospective cohort studies. We searched several bibliographic databases, grey literature sources, conference proceedings and ongoing trials. Our pre?specified primary outcomes were all cause and DILI related mortality, time to normalization of liver biochemistry and adverse events. Secondary outcomes were proportion receiving liver transplant, time to transplantation, transplant?free survival and hospitalization duration. Results: We identified one RCT of NAC vs. placebo in patients with non?paracetamol acute liver failure. There was no difference in the primary outcomes of overall survival at 3 weeks between NAC [70%, 95% confidence interval (CI) = 60%, 81%, n = 81] and placebo (66%, 95% CI = 56%, 77%, n = 92). NAC significantly improved the secondary outcomes of transplant?free survival compared with placebo: 40% NAC (95% CI = 28%, 51%) vs. 27% placebo (95% CI = 18%, 37%). A subgroup analysis according to aetiology found improved transplant?free survival in patients with non?paracetamol DILI, NAC (58%, n = 19) vs. placebo (27%, n = 26), odds ratio (OR) 0.27 (95% CI = 0.076, 0.942). Overall survival was similar, NAC (79%) vs. placebo (65%);, OR 0.50 (95% CI = 0.13, 1.98). Conclusion: Current available evidence is limited and does not allow for any firm conclusions to be made regarding the role of NAC in non?paracetamol DILI. We therefore highlight the need for further research in this area. äN?acetylcysteine for non?paracetamol drug?induced liver injury: a syst(epmc).pdf DeepDyve Pubget Overpricing